NAFLD Clinical Trial - Randomized Double Blinded Placebo-Controlled

Status Recruiting

Clinical Trial Summary

In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.

Clinical Trial Description

Weight gain following LT is common and a risk for cardiovascular disease and development of NAFLD. Developing NAFLD following LT can lead to patients developing scar tissue in the graft (transplanted liver), and graft-cirrhosis. These events can limit the benefit of the transplanted liver graft and reduce the benefit of LT as a therapy. Current weight management strategies have not been successful at the prevention of these events in most patients. This highlights a substantial unmet need for effective treatment to prevent or reduce post-LT weight gain and highlight the importance of new treatment strategies for reducing illness, death, and healthcare cost associated with post-LT weight gain. The purpose of this research study is to test the safety, tolerability, and effectiveness of semaglutide when used to prevent weight gain after liver transplant. Semaglutide is a drug that has been approved by the U. S. Food and Drug Administration (FDA) for treatment of obesity and Type 2 Diabetes. Semaglutide, has shown to be effective for not only weight loss but also long-term weight maintenance. Semaglutide has also shown to be helpful in treatment of nonalcoholic steatohepatitis (NASH) in the non-transplant population. This medication also is used to control blood sugar and prevent cardiovascular disease, which contributes to poor outcomes in LT recipients. Thus, the purpose of the present study is to determine if use of semaglutide early after LT can (1) reduce weight gain and (2) prevent development of NAFLD following LT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05424003
Study type	Interventional
Source	Virginia Commonwealth University
Contact	Sherry Boyett, RN
Phone	804-828-5434
Email	sherry.boyett@vcuhealth.org
Status	Recruiting
Phase	Phase 2
Start date	February 22, 2024
Completion date	February 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06101433` - The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A	N/A
Completed	`NCT03289897` - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan	N/A
Active, not recruiting	`NCT05479721` - LITMUS Imaging Study
Completed	`NCT05527938` - Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children	N/A
Recruiting	`NCT06308757` - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis	N/A
Completed	`NCT02654977` - CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy	Phase 2
Completed	`NCT02927184` - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease	Phase 2
Completed	`NCT06047847` - Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption	N/A
Active, not recruiting	`NCT03534908` - Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
Recruiting	`NCT06098417` - Biomarkers in the Diagnosis and Prognosis of NAFLD
Recruiting	`NCT04564391` - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins	N/A
Not yet recruiting	`NCT05984745` - Effect of CoQ10 on the Outcome of MAFLD Patients	Phase 2
Not yet recruiting	`NCT05052515` - The Effects of Natural Extracts Supplementation on NASH Patients	N/A
Recruiting	`NCT02459496` - Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus	N/A
Completed	`NCT01936779` - Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans	N/A
Completed	`NCT05844137` - Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes	N/A
Recruiting	`NCT04664036` - Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
Recruiting	`NCT04976283` - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver	Phase 4
Recruiting	`NCT03587298` - Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
Completed	`NCT02952170` - Impact of Weight Loss Surgery in Adolescents With NAFLD	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms